UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~March 2809, 2022 (March 4, 2022)

KALEIDO BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-38822	47-3048279
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

65 Hayden Avenue
Lexington, Massachusetts		02421
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 674-9000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 Par Value	KLDO	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 85.0102 ~~Other~~Departure ~~Events~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~The~~On ~~Company~~March ~~has~~4, ~~decided~~2022, toJerald ~~halt~~Korn, ~~work~~the onGeneral aCounsel ~~planned~~and ~~Phase~~Chief 2Operating ~~chronic~~Officer ~~obstructive~~of ~~pulmonary~~Kaleido ~~disease~~Biosciences, Inc. (~~COPD~~the “Company”), ~~study~~submitted ~~and~~notice ~~terminate~~to ~~its~~the ~~agreement~~Company ~~with~~of ~~the~~his ~~COPD~~resignation, ~~Foundation~~effective March 18, 2022, to pursue another opportunity. ~~These~~ ~~decisions~~The ~~were~~Company ~~made~~will inbe ~~order~~entering into a consulting agreement with Mr. Korn pursuant to ~~re-align~~which ~~resources~~Mr. Korn will provide general administrative and ~~focus~~other corporate services to the Company's ~~efforts~~through April 30, 2022. The Company thanks Mr. Korn for his contributions.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Kaleido Biosciences, Inc.
			KALEIDO BIOSCIENCES, INC.
Date:	~~January~~March 289, 2022	By:	/s/ Daniel L. Menichella
			Chief Executive Officer, President and Director
			Daniel L. MenichellaChief Executive Officer, President and Director

Filing Compare · Kaleido Biosciences, Inc.